R&D-oriented pharmaceutical firms to benefit from exemption of drug price cut

Published: 2010-10-08 06:58:00

Updated: 2010-10-08 06:58:00

The drug price cut will be significantly exempted for drugmakers who intend to spend more money on the research and development (R&D) of new drugs, according to the Ministry of Health and Welfare.

Pharmaceutical manufacturers making an investment of 50 billion won in their R&D projects will ha...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK